Pomerantz says Embecta investors face Aug. 17 lead-plaintiff deadline
Pomerantz LLP says it filed a securities class action against Embecta Corp. and is telling investors they have until Aug. 17, 2026, to ask the court to appoint them lead plaintiff.
Pomerantz LLP says it filed a securities class action against Embecta Corp. and is notifying investors that they have until Aug. 17, 2026, to ask a court to appoint them as lead plaintiff.
The notice says the case concerns whether Embecta and certain officers or directors engaged in securities fraud or other unlawful business practices. Embecta trades on Nasdaq under the ticker EMBC.
According to the notice, Embecta said on May 5 that it had missed second-quarter guidance and lowered its fiscal 2026 outlook. The company also disclosed that revenue fell more than 14%, compared with guidance for results to be flat to down 2%. Pomerantz said Embecta lowered U.S. performance estimates largely because of weakness in pen needle sales.
The notice says Embecta stock fell nearly 58% after that announcement. Pomerantz did not provide a separate court filing in the alert beyond saying the class action had been filed.
Investors who purchased or otherwise acquired Embecta securities during the class period may ask the court to appoint them as lead plaintiff, the notice says. Pomerantz identified Danielle Peyton as the contact for inquiries and said e-mail requests should include a mailing address, telephone number and the number of shares purchased.
The notice also says a copy of the complaint can be found at pomerantzlaw.com.
The next date listed in the notice is the Aug. 17 deadline for lead-plaintiff requests.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()